- AIDS
acquired immunodeficiency syndrome
- ART
antiretroviral therapy
- BD
twice daily
- CEA
cost effectiveness analysis
- CEM
cohort event monitoring
- CI
confidence interval
- CHMP
Committee for Medicinal Products for Human Use
- DDI
drug drug interaction
- DoI
declaration of interests
- DOT
directly observed treatment
- DOTS
basic package that underpins the WHO Stop TB Strategy
- DST
drug-susceptibility testing
- ECG
electrocardiogram
- EG
Expert Group
- ERP
External Review Panel
- EMA
European Medicines Agency
- GTB
WHO Global TB Programme
- GRADE
Grading of Recommendations, Assessment, Development and Evaluation
- GRC
Guidelines Review Committee
- HIV
human immunodeficiency virus
- ITT
intention to treat
- MDR-TB
multidrug-resistant tuberculosis
- MIC
minimal inhibitory concentration
- MGIT
mycobacteria growth indicator tube liquid culture system
- MITT
modified intention to treat
- NTP
national tuberculosis programme
- OBR
optimized background regimen
- PICO
population, intervention, comparator, outcome
- PLHIV
people living with HIV
- PMDT
programmatic management of drug-resistant tuberculosis
- QT
the interval from the beginning of the QRS complex to the end of the T wave on an electrocardiogram
- QTcF
QT interval corrected for heart rate according to the Fridericia method
- RCT
randomized controlled trial
- RR
relative risk
- SAE
severe adverse event
- SCC
sputum culture conversion
- SRA
stringent regulatory authority
- SSM
sputum-smear microscopy
- TB
tuberculosis
- TEAE
treatment-emergent adverse effects
- USAID
United States Agency for International Development
- XDR-TB
extensively-drug resistant tuberculosis
- WHO
World Health Organization
